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Abstract Hemimegalencephaly (HMEG) is a develop-
mental brain malformation highly associated with epilepsy.
Balloon cells (BCs) and cytomegalic neurons (CNs) are
frequently observed in HMEG specimens. Cytomegaly in
developmental brain malformations may reXect in aberrant
activation of the mTOR and -catenin signaling cascades,
known regulators of cell size. We hypothesized that there is
aberrant co-expression of phospho-ribosomal S6 (P-S6)
protein, a downstream eVector of the mTOR cascade, as
well as cyclin D1, a downstream eVector of the -catenin
pathway, in BCs and cytomegalic neurons in HMEG. We
hypothesized that mutations in PTEN (a cause of HMEG
associated with Proteus syndrome), TSC1 or TSC2 (tuber-
ous sclerosis complex) genes, which are known to modulate
-catenin and mTOR signaling could cause sporadic
HMEG. Expression of cyclin D1, phospho-p70 S6 kinase
(P-p70S6K, another mTOR cascade kinase), P-S6, MAP2,
NeuN, or GFAP was determined by immunohistochemistry
in HMEG brain tissue (n = 7 specimens). Cyclin D1, P-
p70S6K, and P-S6 proteins were co-localized in BCs and
CNs in the enlarged hemisphere but not in the unaVected
hemisphere or in morphologically normal tissue. Cyclin D1
and P-S6 proteins were not detected in GFAP-labeled astro-
cytes. Sequencing of PTEN, TSC1, and TSC2 genes in cyto-
megalic cells co-expressing cyclin D1 and P-S6 proteins
did not reveal mutations. Selective expression of cyclin D1
and P-S6 in cytomegalic cells in HMEG suggests co-activa-
tion of the -catenin and mTOR cascades. PTEN, TSC1, or
TSC2 gene mutations were not detected suggesting that
sporadic HMEG is distinct from HMEG associated with
Proteus syndrome or tuberous sclerosis complex.
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Introduction
Hemimegalencephaly (HMEG) is a dramatic malformation
of cortical development characterized by marked enlarge-
ment and cytoarchitectural abnormalities in one cerebral
hemisphere [7, 8, 18]. HMEG is highly associated with
early onset intractable epilepsy [7, 8, 18]. Balloon cells
(BCs) and cytomegalic neurons (CNs) morphologically
similar to those observed in cortical dysplasia (cortical dys-
plasia with balloon cells, CDBC) or to giant cells (GCs) in
tuberous sclerosis complex (TSC) tubers are detected in
many, although not in all, HMEG cases [6–8, 18]. The
molecular pathogenesis of HMEG remains poorly under-
stood in part because HMEG is typically a sporadic disor-
der and thus large family pedigrees cannot be assessed. One
hypothesis is that HMEG results from a somatic gene muta-
tion occurring in neuroglial progenitor cells during brain
development [6].
From a mechanistic prospective, the -catenin and
mTOR (mammalian target of rapamycin) cascades are ideal
candidates to study in HMEG because activation of these
cellular pathways leads to accelerated cell growth [9, 15,
16]. Previous studies have demonstrated that there is altered
-catenin signaling in CDBC [5]. BCs and CNs in CDBC
and hemispheric dysplasia as well as GCs in TSC express
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tor of the mTOR cascade [1, 12, 14]. Enhanced expression
of activated -catenin in HMEG is associated with
increased levels of cyclin D1, c-myc, and WISP-1 mRNA
that are transcriptionally activated by the -catenin path-
way [19]. These results in human tissue are supported
experimentally because constitutive activation of -catenin
in transgenic mice leads to megalencephaly [4] and
enlarged astrocytes cultured from mice lacking Tsc1
express high levels of P-S6 [19].
We assayed the expression of cyclin D1, phospho-p70
S6 kinase (P-p70S6K), and P-S6 proteins in HMEG as a
strategy to determine whether -catenin and mTOR activa-
tion is linked to cytomegaly and hemispheric enlargement.
Because HMEG has been reported in TSC patients [3] and
in Proteus syndrome patients associated with mutations in
the PTEN gene [21], and mTOR is directly modulated by
PTEN and the TSC1/TSC2 complex [13, 16], the PTEN,
TSC1 and TSC2 genes were sequenced in DNA extracted
from HMEG tissue to determine whether aberrant expres-
sion of cyclin D1, P-p70S6K, and P-S6 proteins in HMEG
results from somatic PTEN or TSC gene mutations.
Methods
Tissue specimens
HMEG specimens (n = 7; 4 males, 3 females; ages 2–
24 months) were obtained following epilepsy surgery
(n = 5) or at post-mortem examination (n = 2; cause of
death was cardiac arrest). One case was associated with lin-
ear nevus syndrome, one case with Klippel–Trenaunay–
Weber syndrome, and the remaining cases were without
any syndromic association. All patients had intractable epi-
lepsy. Histological examination revealed absent cortical
lamination, cytomegalic neurons, and BCs throughout the
cortex. In two post-mortem cases, the unaVected hemi-
sphere was histologically intact.
Frontal lobe neocortex was obtained from two sets of
control patients. First, age-matched normal control cortex
was obtained post-mortem (1, 4, 7 months and 1 year, 2
males and 2 females) from individuals without a history of
epilepsy. Second, frontal cortex was obtained during epi-
lepsy surgery from patients without cortical malformation
(epilepsy control cases; n = 4, mean age 2.7 years, 2 males
and 2 females). Studies were approved by the University of
Pennsylvania Institutional Review Board.
Immunohistochemistry
ParaYn embedded, 7 m sections were probed with cyclin
D1 (monoclonal rabbit, clone SP4, Lab Vision Corporation,
Fremont, CA, USA; 1:100), glial Wbrillary acidic protein
(GFAP; polyclonal rabbit, DAKO, Glostrup, Denmark;
1:4,000), microtubule-associated protein-2 (MAP2; mouse
clone HM2, IgG1; SIGMA, St. Louis, MO, USA; 1:100
and polyclonal rabbit, Chemicon; 1:1,000), neuronal
nuclear protein (NeuN; mouse clone MAB377, IgG1;
Chemicon, Temecula, CA, USA; 1:1,000), P-S6 protein
(Ser235/236; monoclonal rabbit, Cell Signaling Technol-
ogy, Beverly, MA, USA; 1:100) and P-p70S6K (Thr389;
monoclonal mouse; Cell Signaling 1:200), antibodies at 4°C
overnight. Single-label immunohistochemistry was visualized
using avidin–biotin peroxidase method and 3,3-diam-
inobenzidine as chromogen.
For double-labeling studies, the cyclin D1 antibody
was removed by microwave oven treatment (sodium cit-
rate buVer, 0.01 M, pH 6.0; 650 W for 10 min). Sections
were then pre-incubated with 10% goat serum and incu-
bated for 1 h at room temperature with the second primary
antibody (GFAP, MAP-2 or P-S6). Following biotiny-
lated secondary antibody, labeling was visualized with the
avidin–biotin peroxidase method and liquid permanent
red as a chromogen (DAKO). Sections were counter-
stained with haematoxylin. Digital photomicrographs
were generated through contiguous regions of each
HMEG sample to deWne immunolabeling proWles for P-S6
and cyclin D1.
For cyclinD1/NeuN double-labeling studies, sections
(after incubation with primary antibodies) were incubated
for 2 h with Alexa Fluor® 568 and Alexa Fluor® 488
(anti-rabbit IgG or anti-mouse IgG; 1:200; Molecular
probes, Eugene, USA). Sections were then analyzed by
means of a laser scanning confocal microscope (Bio-Rad,
Hercules, CA, USA; MRC1024) equipped with an argon-
ion laser.
Quantitative cell counts
The BCs and CNs were deWned using morphometric
parameters (maximal cell diameter and process extension)
based on NeuN staining for quantitative cell counting
analysis applied to immunohistochemically labeled sec-
tions. Representative contiguous digital photos were
obtained (20£ magniWcation) from each tissue section
using image acquisition and analysis software (Spot RT
CCD camera, Diagnostic Instruments, Inc. and Phase 3
Imaging System integrated with Image Pro Plus; Media
Cybernetics, Silver Spring, MD, USA) [11]. The contigu-
ous images spanned a 1 cm2 region of interest (ROI) in
each specimen and were generated under light and phase
contrast optics to maximize identiWcation of cell morphol-
ogy. Prior to Wnal assignment as BCs or CNs by the soft-
ware, each ROI was visually inspected and any cellular
elements erroneously included in the computerized analysis123
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largest aspect) across the total numbers of morphologi-
cally identiWed BCs and CNs was calculated using Image
ProPlus software (expressed in microns by direct calibra-
tion with a micrometer). Cytomegaly was operationally
deWned as a maximal cell soma diameter of greater than
120 m.
Cell microdissection and PTEN/TSC1/TSC2 
gene sequencing in HMEG
For the DNA sequencing studies, single P-S6 immunoreac-
tive BCs (n = 100) visualized under light microscopy were
microdissected with CellPixII laser capture system (Arctu-
rus) from each case. We selected BCs for analysis because
these cells exhibit the most dramatic cytomegaly in HMEG.
Cells were eluted from the dissection caps, and genomic
DNA was extracted from the pooled dissected cells (Qiagen
DNA extraction kit). Genomic DNA was extracted
(Qiagen) from the HMEG specimens or unaVected hemi-
sphere in the two post-mortem cases. Exon-speciWc Xank-
ing PCR primers (forward and reverse) were generated
to human TSC1, TSC2 and PTEN genes, and amplicons
from all exons were sequenced (ABI Prism). All PCR and
sequencing reactions were performed in duplicate and in
forward and reverse directions. TSC1/TSC2 sequence
results were compared with existing database sequence for
TSC1 and TSC2 (http://www.chromium.liacs.nl/lovd/index.
php?select_db = TSC1 or db = TSC2) and for PTEN (http://
www.ncbi.nlm.nih.gov/Genbank/index.html).
Results
Co-expression of P-S6 and cyclin D1 proteins
The expression of P-S6 and phospho-p70 S6 kinase pro-
teins was nearly absent in normal control cortex, epilepsy
control cortex, and the unaVected hemispheres from the two
post-mortem HMEG cases (Fig. 1). In contrast, there was
robust cytoplasmic P-S6 protein labeling in BCs and CNs
present in all seven HMEG cortical specimens (Fig. 1).
Cytomegalic neurons exhibited a clear neuronal morphol-
ogy with apical dendrites and basal axons, whereas BCs
exhibited a dysmorphic, ovoid soma, laterally displaced
nucleus, and minimal dendritic or axonal extensions.
Labeled cells were observed throughout the thickness of the
cortex as well as within the heterotopic cells in the subcorti-
cal white matter. P-p70S6K expression was also conWned to
cytomegalic cells in the HMEG cases but was less robust
than P-S6 as has been previously reported in TSC [1, 14]
(Fig. 2). Because P-S6 is the Wnal endpoint of mTOR cas-
cade activation we used computer-assisted cell counting
[see 11] to assess the relationship between P-S6 expression
and cytomegaly. Across all ROIs, 94 § 9% of cells that met
morphological criteria for cytomegaly (maximal cell diam-
eter greater than 120 m) exhibited cytoplasmic P-S6
expression, whereas P-S6 expression in smaller cells (less
than 90 m) was nearly absent. Further subgroup analysis
based on morphometric parameters demonstrated that
91 § 9% of BCs and 81 § 11% CNs exhibited P-S6 label-
ing across the ROIs.
Cyclin D1 expression was not detected in normal control
cortex, epilepsy control cortex, or the unaVected hemi-
spheres from the two post-mortem HMEG cases (Fig. 3).
Nuclear cyclin D1 labeling was noted in all the HMEG
specimens throughout the full thickness of the cortex
(Fig. 3). The expression of nuclear cyclin D1 co-localized
with P-S6 labeling in BCs and CNs in HMEG across the
thickness of the cortex. Many cells that exhibited P-S6
labeling also expressed nuclear cyclin D1, and few cyclin
D1-labeled cells were devoid of P-S6 labeling. The expres-
sion of nuclear cyclin D1 co-localized with P-S6 labeling in
BCs and CNs in HMEG in 87 § 6% of morphologically
identiWed cytomegalic cells (greater than 120 m; Fig. 4)
but was not detected in the remaining cells less than
100 m in size.
The morphology of many double-labeled cyclin D1
and P-S6 cells was typical of CNs, and in a second set of
experiments we show that CNs exhibiting either P-S6 or
cyclin D1 labeling co-expressed the neuronal marker
proteins, NeuN (Fig. 3) or MAP2 (Fig. 4). In fact, co-
labeling of sections with vimentin (a marker for imma-
ture astrocytes; Fig. 3) or GFAP (Fig. 4) and either
cyclin D1 or P-S6 antibodies demonstrated that vimentin
or GFAP-labeled cells exhibiting an astrocytic morphol-
ogy did not co-express cyclin D1 or P-S6 proteins. In a
subpopulation of BCs in all HMEG specimens, vimentin
and either P-S6 or cyclin D1 were co-expressed (not
shown).
We were unable to make any correlations between clini-
cal phenotype (age, age at seizure onset, duration of sei-
zures, or surgical outcome) and protein marker expression
in our sample.
PTEN/TSC1/TSC2 gene sequencing in HMEG
Full exon sequencing of TSC1, TSC2, and PTEN in geno-
mic DNA extracted from HMEG specimens did not reveal
mutations. Several previously identiWed and synonymous
PTEN, TSC1 and TSC2 gene sequence polymorphisms
were identiWed in all. In the two post-mortem cases, identi-
cal polymorphisms were detected in DNA extracted from
the unaVected and enlarged hemispheres suggesting that
these sequence alterations were not associated with hemi-
spheric enlargement.123
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We demonstrate that there is aberrant expression of cyclin
D1, p70S6K, and P-S6 proteins in HMEG specimens con-
taining BCs and CNs. These proteins were not detected in
the morphologically intact hemisphere in two post-mortem
HMEG cases suggesting that cyclin D1, P-p70S6K, and
P-S6 protein expression are associated with hemispheric
enlargement in HMEG. In addition, these results in combi-
nation with near absent cyclin D1, P-p70S6K, and P-S6
expression in non-HMEG brain tissue resected from
patients with intractable epilepsy argue that expression of
these proteins did not reXect the eVects of recurrent seizures
or anti-epileptic drugs. Co-expression of cyclin D1 and
P-S6 proteins overlapped with NeuN and MAP2, but not
GFAP, expression suggesting that cyclin D1 and P-S6 pro-
tein expression was conWned to cells exhibiting neural line-
age markers. Sequence analysis did not detect mutations
in PTEN, TSC1, or TSC2 in HMEG tissue. However, the
enhanced expression of cyclin D1, P-p70S6K, and P-S6
suggests for the Wrst time two cell cascades that may be
related to the pathogenesis of HMEG. Since BCs are not a
universal Wnding in HMEG, our results suggest that there
may be distinct subtypes of HMEG characterized by the
presence or absence of BCs that form by distinct patho-
genic mechanisms.
Fig. 1 Expression of P-S6 
protein in HMEG. a minimal 
P-S6 expression in control 
cortex compared with robust 
expression in HMEG (b scale 
bar a and b, 500 microns). 
Panels c–h depict P-S6 expres-
sion in cytomegalic neurons
(c and inset, d, f, g) and balloon 
cells (E, F, h, scale bar 
60 microns)
Fig. 2 Expression of phospho-
p70 S6 kinase (P-p70S6K) in 
HMEG. Note presence of P-
p70S6K in cytomegalic cells in 
low (scale bar, 450 microns) and 
high (scale bar, 200 microns) 
power Welds123
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cytomegalic cells providing evidence that there is cell
selective activation of these two cascades. In terms of cell
lineage, co-expression of cyclin D1 and P-S6 proteins did
not overlap with GFAP expression but did co-localize with
NeuN expression suggesting that activation of the -catenin
and mTOR cascades was conWned to cells exhibiting neural
lineage markers. Cyclin D1 expression is transcriptionally
activated through -catenin signaling and is an important
marker for cells undergoing mitosis [12, 14]. Increased
expression of nuclear cyclin D1 protein in HMEG corrobo-
rates our earlier Wndings of increased cyclin D1 mRNA
expression in HMEG and suggests hypothesis that enhanced
-catenin signaling may be related pathogenically to
HMEG [20].
The -catenin and mTOR pathways are linked through
TSC1 and TSC2. The TSC1/TSC2 complex promotes -
catenin degradation via association with GSK3 and axin
and inhibits Wnt-stimulated gene transcription. Loss of
function of TSC1 or TSC2 leads to ribosomal S6 phosphor-
ylation and enhanced -catenin signaling [15]. Thus, aber-
rant expression of cyclin D1 and P-S6 in cytomegalic cells
in HMEG highlights two pivotal cell growth pathways that
may contribute to abnormal cortical development. The fact
that more than 90% of cytomegalic cells co-expressed both
proteins supports the hypothesis that the aberrant -catenin
and mTOR signaling leads to progressive cellular enlarge-
ment in HMEG. Indeed, cells lacking TSC1, TSC2, or
PTEN in vitro exhibit progressive cytomegaly [10, 19]. The
absence of cyclin D1 and P-S6 in the unaVected hemi-
spheres from two HMEG cases, further demonstrates the
potential pathogenic speciWcity of these pathways in
HMEG in relation to enhanced hemispheric and cellular
size.
The association between phosphorylation of ribosomal
S6 protein and enhanced protein synthesis, increased cell
size, and expansive tissue growth has been clearly demon-
strated in TSC [1, 17]. Interestingly, mutations in PTEN,
which negatively regulates both mTOR and -catenin sig-
naling [15], have been demonstrated in HMEG associated
with Proteus syndrome [19]. Non-synonymous polymor-
phisms have been reported in PTEN and TSC1 in CDBC
[2, 17]; however, no functional PTEN or TSC gene poly-
morphisms or mutations were detected in our sample of
sporadic HMEG cases. These data suggest that sporadic
HMEG is genetically distinct from HMEG associated with
Fig. 3 Expression of cyclin D1 
in HMEG. a near absence of 
cyclin D1 expression in control 
cortex compared with b, robust 
nuclear expression in HMEG 
(scale bar a and b, 500 microns). 
c, d depict higher power views 
of nuclear cyclin D1 labeling. e, 
f cyclin D1 expression in neuron 
conWrmed by co-localization of 
cyclin D1 and NeuN expression 
(f, and inset). g nuclear cyclin 
D1 and inset, distinct labeling 
proWle for cyclin D1 (red) and 
vimentin (green) a marker for 
immature astrocytes (scale bar 
e, f, g, 60 microns)123
292 Acta Neuropathol (2007) 114:287–293Proteus syndrome or TSC. A mutation in another candidate
gene known to co-regulate both pathways seems plausible.
Enhanced co-expression of cyclin D1 and P-S6 proteins
in a subset of HMEG specimens containing BCs and cyto-
megalic neurons provides a new insight into how HMEG
may form during cortical development. These results sup-
port the hypothesis that co-activation of the -catenin and
mTOR cascades contributes to cytomegaly and hemi-
spheric enlargement in HMEG.
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